<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The transcription factor Nuclear factor kappa B (NF-kappaB) is central to the regulation of genes encoding for mediators of <z:mp ids='MP_0001845'>inflammation</z:mp> and <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In the esophagus, NF-kappaB is progressively activated from <z:mp ids='MP_0001845'>inflammation</z:mp> to Barrett's <z:mpath ids='MPATH_160'>metaplasia</z:mpath> and <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="122" ids="21241">Vitamin C</z:chebi>, an <z:chebi fb="11" ids="22586">antioxidant</z:chebi>, can inhibit NF-kappaB in in vitro models, and the aim of this study was to prospectively assess the effect of supplemental <z:chebi fb="122" ids="21241">vitamin C</z:chebi> on NF-kappaB and associated cytokines in patients with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Twenty-five patients with long-segment Barrett's and specialized <z:mpath ids='MPATH_167'>intestinal metaplasia</z:mpath> received dietary <z:chebi fb="122" ids="21241">vitamin C</z:chebi> (1000 mg/day) orally for four weeks, and had pre- and post-<z:chebi fb="122" ids="21241">vitamin C</z:chebi> endoscopic biopsies </plain></SENT>
<SENT sid="4" pm="."><plain>NF-kappaB activity (activated p50 and p65 subunits) of nuclear extracts was assessed using the Active Motif NF-kappaB assay, and cytokines and growth factors were measured using the Evidence Investigator biochip array </plain></SENT>
<SENT sid="5" pm="."><plain>NF-kappaB and related pro-inflammatory cytokines and growth factors (IL-8, VEGF, IL-10) were activated in <z:hpo ids='HP_0000001'>all</z:hpo> Barrett's tissue pre-treatment </plain></SENT>
<SENT sid="6" pm="."><plain>Down-regulation in activated NF-kappaB and cytokines was observed in 8/25 (35%) patients </plain></SENT>
<SENT sid="7" pm="."><plain>Dietary <z:chebi fb="122" ids="21241">vitamin C</z:chebi> supplementation may down-regulate pro-inflammatory markers in a subset of Barrett's patients </plain></SENT>
<SENT sid="8" pm="."><plain>Further studies with larger numbers of endpoints will be needed to further evaluate this effect </plain></SENT>
</text></document>